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A B S T R A C T
Purpose
BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed
death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across
lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or
tumor-infiltrating immune cells (IC).
Patients and Methods
Eligible patients had advanced-stage NSCLC, no CNSmetastases, and zero to two or more lines of prior
chemotherapy. Patientswhose tumors expressedPD-L1 using the SP142 immunohistochemistry assay
on$ 5%of TCor IC (TC2/3 or IC2/3 [TCor IC$ 5%PD-L1–expressing cells, respectively])were enrolled.
Atezolizumab 1,200mgwas administered intravenously every 3weeks. Efficacy-evaluable patients (N =
659) comprised three cohorts: first line (cohort 1; n =139); second line (cohort 2; n =268); and third line or
higher (cohort 3; n = 252). The primary end point was independent review facility–assessed objective
response rate (ORR; Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Secondary end
points included median duration of response, progression-free survival, and overall survival (OS).
Results
BIRCH met its primary objective of demonstrating a significant ORR versus historical controls. With
a minimum of 12 months of follow-up, the independent review facility–assessed ORR was 18% to
22% for the three cohorts, and 26% to 31% for the TC3 or IC3 subgroup;most responses are ongoing.
Responses occurred regardless of EGFR or KRAS mutation status. The median OS from an updated
survival analysis (minimum of 20month follow up) for cohort 1 was 23.5months (26.9months for TC3
or IC3 patients); themedian OS in cohorts 2 and 3 was 15.5 and 13.2 months, respectively. The safety
profile was similar across cohorts and consistent with previous atezolizumab monotherapy trials.
Conclusion
BIRCH demonstrated responses with atezolizumab monotherapy in patients with PD-L1–selected
advanced NSCLC, with good tolerability. PD-L1 status may serve as a predictive biomarker for
identifying patients most likely to benefit from atezolizumab.
J Clin Oncol 35:2781-2789. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Patients with advanced non–small-cell lung cancer
(NSCLC) have onlymodest improvements in survival
with systemic therapies. First-line (1L) treatment with
platinum-based chemotherapy generally results in
median overall survival (mOS) of 8 to 10 months.1
Combining antiangiogenic therapy with chemo-
therapy can improve response rates and survival
in patients with nonsquamous histology.2 Second-
line (2L) chemotherapy results in small in-
creases in survival (median survival approximately
9 months).3,4 Patients with tumors that harbor
epidermal growth factor receptor (EGFR) and
anaplastic lymphoma kinase (ALK) driver alter-
ations have high responses and improvements in
survival when treated upfront with tyrosine kinase
inhibitors; however, more effective treatments are
needed for most patients with NSCLC.
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Immune checkpoint inhibitors have demonstrated efficacy
and improved survival in various cancers, including advanced
NSCLC,5-8 and agents targeting programmed death-ligand 1 (PD-
L1) and/or programmed death 1 (PD-1)—atezolizumab, nivolu-
mab, and pembrolizumab—have been approved for use in
NSCLC.5,7,9-12 PD-L1 is an immune checkpoint protein expressed
on tumor cells (TC) and tumor-infiltrating immune cells (IC).13
Binding of PD-L1 to its receptors, PD-1 and B7.1 (CD80), on
activated T cells can dampen the T-cell immune response and
promote tumor immune escape.14-16 Targeting PD-L1 and PD-1 can
relieve this inhibition and increase tumor-specific T-cell immunity.
Atezolizumab is an engineered humanized anti–PD-L1 im-
munoglobulin G1 monoclonal antibody that binds PD-L1 and
inhibits PD-L1–mediated signaling. It has demonstrated clinical
efficacy in various solid tumors and is approved in $ 2L urothelial
bladder cancer, 1L cisplatin-ineligible urothelial bladder cancer, and
NSCLC.12,17-21 Atezolizumab is the first anti–PD-L1 antibody to
demonstrate efficacy in both chemotherapy-naı̈ve and previously
treated advanced NSCLC.21-24 Studies suggested that PD-L1 ex-
pression on TC and IC was an independent predictor of response
to atezolizumab, and that its efficacy increased with PD-L1
expression.21,23 The phase II trial presented herein, BIRCH, was
designed to assess the efficacy and safety of single-agent atezoli-
zumab in patients with PD-L1–selected stage IIIB/IV NSCLC,
across multiple lines of therapy.
PATIENTS AND METHODS
Study Design and Patients
BIRCH is a phase II, global, multicenter, single-arm trial of atezo-
lizumab in patients with PD-L1–selected locally advanced or metastatic
NSCLC. All patients were tested at enrollment for PD-L1 positivity on TC
and IC using the SP142 immunohistochemistry assay (Ventana Medical
Systems, Tucson, AZ) on archival or freshly collected tumor specimens, as
determined in a central laboratory. This assay is sensitive and specific for
PD-L1 expression on TC and IC.17 PD-L1 TC expression was scored as
a percentage of PD-L1–positive TC (TC3 $ 50% or TC2 $ 5%
but, 50%). PD-L1 IC expressionwas scored as a percentage of tumor area
stained positive (IC3$ 10% or IC2$ 5% but, 10%; Appendix Table A1,
online only).
BIRCH comprised three patient cohorts (Fig 1): cohort 1 (no prior
chemotherapy for advanced NSCLC [1L]); cohort 2 (progression during or
following no more than one prior platinum-based regimen for advanced
NSCLC [2L]); and cohort 3 (progression during or following at least two
prior chemotherapy regimens for advanced disease [$ 3L {third line}]).
The study protocol and amendments were approved by institutional
review boards or ethics committees. BIRCH was conducted in accor-
dance with the Declaration of Helsinki and International Conference on
Harmonisation Guidelines for Good Clinical Practice. All patients pro-
vided written informed consent. BIRCH was sponsored by Genentech Inc.
(a member of the Roche Group) which provided the study drug, atezo-
lizumab (ClinicalTrials.gov identifier: NCT02031458).
Study Assessments
The primary efficacy outcome measure was independent re-
view facility (IRF)–assessed objective response rate (ORR) per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary
efficacy outcomemeasures included IRF-assessed progression-free survival
(PFS) and duration of response (DOR); investigator-assessed ORR, PFS,
and DOR; OS; and safety. IRF-assessed ORR, DOR, PFS, and OS as well as
safety analyses were on the basis of a data cutoff of December 1, 2015. An
updated OS analysis was also conducted on the basis of an August 1, 2016,
data cutoff (minimum 20-month follow-up). Alterations in EGFR, KRAS,
and ALK were determined by the FoundationOne panel (Foundation
Medicine, Cambridge, MA)25 and/or local tests. Tumors were considered
EGFR or KRAS mutant if the mutation was detected by either testing
method; those without either test result were considered missing.
Patients
Key eligibility criteria included histologically or cytologically con-
firmed stage IIIB/IV or recurrent NSCLC, age $ 18 years, tumor PD-L1
expression (TC2/3 or IC2/3 [TC or IC $ 5% PD-L1–expressing cells,
Cohort 2 (2L)





Cohort 3 (≥ 3L)
At least two prior chemotherapies 
(including one platinum)
(n = 254)
Until loss of clinical benefitPD
Study End Points
Primary: IRF-assessed ORR per RECIST v1.1
Secondary: IRF-assessed PFS, DOR per RECIST v1.1; 
INV-assessed ORR, PFS, DOR per RECIST v1.1 and modified RECIST, OS, safety
Locally advanced or metastatic NSCLC
Tumor PD-L1 expression by IHC (TC2/3 and/or IC2/3)
ECOG PS 0 or 1
No brain metastases
  (N = 667)
Fig 1. Atezolizumab was administered at
a fixed dose of 1,200mg intravenously on day
1 every 3weeks in all cohorts. TC3 or IC3 = TC
$ 50% or IC $ 10% PD-L1–expressing cells,
respectively; TC2/3 or IC2/3 = TC or IC $ 5%
PD-L1–expressing cells, respectively. 1L, first
line; 2L, second line; 3L, third line; DOR,
duration of response; ECOG, Eastern Coop-
erative Oncology Group; IC, tumor-infiltrating
immune cells; IHC, immunohistochemistry;
INV, investigator; IRF, independent review
facility; NSCLC, non–small-cell lung cancer;
ORR, objective response rate; OS, overall
survival; PD, progressive disease; PD-L1,
programmed death-ligand 1; PFS, progression-
free survival; PS, performance status; RECIST,
Response Evaluation Criteria in Solid Tumors;
TC, tumor cells.
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respectively]), Eastern Cooperative Oncology Group performance status 0 or
1, measurable disease per RECIST version 1.1, and adequate hematologic
and end-organ function. Key exclusion criteria were CNSmetastases, history
of pneumonitis, autoimmune diseases, or chronic viral diseases, and prior
treatment with CD137 agonists or immune checkpoint inhibitors (prior
anti–cytotoxic T-cell lymphocyte antigen-4 treatment was allowed if it was
$ 6 weeks from the last dose). Patients with a sensitizing EGFR or ALK
mutation must have had disease progression or intolerance to an EGFR or
ALK tyrosine kinase inhibitor approved for NSCLC, respectively.
Treatments
For all cohorts, atezolizumab 1,200 mg was administered by in-
travenous infusion every 3 weeks. Patients in cohorts 2 and 3 could
continue treatment as long as they received clinical benefit according to
investigator assessment (absence of both unacceptable toxicity and
symptomatic deterioration attributed to disease progression). Patients in
cohort 1 were required to discontinue atezolizumab at disease progression
per RECIST version 1.1. Dose reductions were not allowed.
Study Assessments
Radiologic tumor assessments were performed every 6 weeks for
12 months, then every 9 weeks thereafter regardless of treatment delays until
disease progression, loss of clinical benefit (patients in cohorts 2 and 3 only),
withdrawal of consent, death, or study termination. This included patients
who discontinued for reasons other than disease progression. All patients
evaluable for safety and efficacy (per RECIST version 1.1) had measurable
disease at baseline and received at least one dose of atezolizumab.
Adverse events (AEs) and laboratory data were summarized and
graded per National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0.
Exploratory Outcome Measures and Biomarkers
Disease control rate was defined as the rate of complete response or
partial response as best confirmed response, or stable disease maintained for
$ 24 weeks. PD-L1 status and exploratory biomarkers such as driver mutation
status were measured in archival and/or freshly obtained tumor tissues.
Statistics
Estimated ORRs in all treated patients (all cohorts) and 95% CIs
were calculated using the Clopper-Pearson method. No formal statistical
comparison of response rates between cohorts was planned. Time-to-event
outcomes (ie, DOR, PFS, and OS) were estimated by the Kaplan-Meier
method. The 95% CIs for median DOR, PFS, and OS were calculated using
the nonparametric Brookmeyer and Crowley method.
The primary efficacy analysis (May 28, 2015) compared IRF-assessed
ORR in prespecified subgroups with prespecified historical control ORRs
in a stepwise fashion using a hierarchical fixed-sequence procedure
(Appendix Table A2, online only; a = 0.05 for each test). Prespecified
chemotherapy historical (2013) control ORRs for previously treated
metastatic NSCLC, used for comparison purposes only, were 5% for$ 3L,
7% for $ 2L, 15% to 20% for 1L, and 15% across all lines.2,26,27
RESULTS
Patients and Treatment
Between January 16, 2014, and December 4, 2014, 3,914
patients were screened for PD-L1 status (36% were PD-L1 TC2/3
or IC2/3), and 667 patients were enrolled from 106 sites in 19
countries. Patient demographic data and baseline characteris-
tics were similar across cohorts (Table 1). The median age was
64 years (range, 28 to 88 years). More than 70% of patients had
nonsquamous tumors. Overall, 46% of patients had TC3 or IC3
tumor PD-L1 status, distributed similarly across cohorts.
A total of 659 patients (99%) received atezolizumab.
The median duration of treatment was 4.2 months (range, 0 to
21months) and the median number of doses was seven (range, one
to 30 doses). Atezolizumab was discontinued in 520 patients
(79%), due to progressive disease (65%), AE (7%), patient decision
(3%), protocol deviation (2%), or physician decision (1%).
Efficacy: ORR, DOR, and PFS
Results from the efficacy analysis performed with a follow-up
of$ 12 months (data cutoff, December 1, 2015) are described in the
following paragraphs. This analysis generally supports the results
from the primary analysis (Appendix Table A2), whichwas performed
with a minimum 6-month follow-up (data cutoff, May 28, 2015).
The IRF-assessed ORR was 22%, 19%, and 18% for cohorts 1, 2,
and 3, respectively (Table 2, Appendix Fig A1 [online only, water-
fall plots], and Appendix Table A3 [TC2 or IC2 subgroup]), with
complete responses in 1%, 2%, and 2% for cohorts 1, 2, and 3,
respectively. For those in the TC3 or IC3 subgroup, the IRF-assessed
ORRwas 31%, 26%, and 27% for cohorts 1, 2, and 3, respectively. The
IRF-assessed ORR was generally higher in smokers and in patients
with nonsquamous NSCLC (Appendix Fig A2, online only). Among
responders, the median DOR was 9.8 months, not estimable (NE),
and 11.8 months for cohorts 1, 2, and 3, respectively. For the TC3 or
IC3 subgroup, median DOR values were 10.0 months, NE, and
7.2 months for cohorts 1, 2, and 3, respectively. Investigator-assessed
efficacy results were generally similar to IRF data (data not shown).
Themedian PFSwas higher for cohort 1 (5.4 months; 95%CI,
3.0 to 6.9 months) than cohort 2 (2.8 months; 95% CI, 1.5 to
3.9 months) and cohort 3 (2.8 months; 95% CI, 2.7 to 3.0 months;
Table 2 and Appendix Fig A3, online only [by TC/IC subgroups]).
Per PFS landmark analysis, 12-month PFS rates were 20%, 17%,
and 14% for cohorts 1, 2 and 3, respectively.
Efficacy: OS
The median duration of survival follow-up for all treated
patients was 14.6 months (95% CI, 14.3 to 14.7 months), on the
basis of a data cutoff of December 1, 2015. The mOSwas highest in
cohort 1 at 20.1 months (95% CI, 20.1 months to NE) compared
with 15.5 months (95% CI, 12.3 months to NE) and 13.2 months
(95% CI, 10.3 to 17.5 months) for cohorts 2 and 3, respectively
(Table 2). The median OS for patients with nonsquamous tumors
was 20.1, 16.3, and 14.7 months in cohorts 1, 2, and 3, respectively,
versus NE, 12.3, and 9.2 months for those with squamous tumors.
In an updated OS analysis (data cutoff, August 1, 2016), with
a median duration of survival follow-up of 22.5 months, mOS
continued to improve. The mOS for cohort 1 was 23.5 months
(95%CI, 18.1 months to NE), and for cohorts 2 and 3 themOSwas
15.5 months (95%CI, 12.3 to 19.3 months) and 13.2 months (95%
CI, 10.3 to 17.5 months), respectively (Table 2 and Fig 2). The
mOS was highest in cohort 1 for the TC3 or IC3 subgroup at
26.9 months (95% CI, 12.0 months to NE). Estimated 12-month
OS rates per landmark analysis for all patients were 66.4%, 58.1%,
and 52.3% for cohorts 1, 2, and 3, respectively. Survival rates
for the TC3 or IC3 subgroup were comparable (Table 2), with
jco.org © 2017 by American Society of Clinical Oncology 2783
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12-month OS rates ranging from 57.5% to 61.5% for the cohorts
exhibiting increased PD-L1 expression.
Safety
Overall, 94% of patients experienced at least one AE, of which
65%were treatment related (Tables 3 and 4). All-cause grade 3 to 4 AEs
occurred in 42% of patients (12% treatment related), with a similar
incidence across cohorts. The AE profile for the TC3 or IC3 subgroup
was generally similar to that for theTC2/3 or IC2/3 patients. Treatment-
related AEs (TRAEs) in$ 10% of treated patients were fatigue (19%),
diarrhea (11%), nausea (11%), and pruritus (10%). Themost common
serious AEs (SAEs, any grade) were pneumonia (4%), dyspnea (3%),
pyrexia (3%), and pneumonitis (2%). One SAE of treatment-related
pneumonia was fatal. AEs of special interest are listed in Table 4.
Forty-three patients (7%) withdrew from treatment due to an
AE (15 [2%] were grade 3 to 4). AEs (any grade; grade 3 to 4)
resulting in withdrawal among all cohorts ($ 0.5%) were pneu-
monitis (1%; 1%) and pneumonia (1%; 0%). Fifteen patients (2%)
withdrew as the result of TRAEs.
There were 305 deaths (46% of patients in the study), 234 of
which occurred $ 30 days after the last administration of ate-
zolizumab; most deaths (90%) were due to disease progression.
The leading cause of death not resulting from progressive disease
was pneumonia (1%).
Exploratory Biomarker Analyses
Tumor tissue was analyzed for EGFR mutations in 543 pa-
tients (82%) and for KRAS mutations in 488 patients (74%;
Table 1). Of those with available results, EGFR mutations were
detected in 8% of patients (11%, 8%, and 7% in cohorts 1, 2, and 3,
respectively), and KRASmutations in 28% of patients (33%, 25%,
and 29% in cohorts 1, 2, and 3, respectively). PD-L1 expressionwas
comparable among TC3 or IC3 patients with EGFR mutations
(range, 21% to 31% for the three cohorts). In subgroup analyses,
responses occurred across lines of therapy regardless of EGFR
status (ORRs for mutant/wild-type tumors in cohorts 1, 2, and 3
were 23%/19%, 0%/21%, and 7%/18%, respectively) or KRAS
status (27%/16%, 32%/16%, and 19%/18% in cohorts 1, 2, and 3,
respectively; Table 2). There was an insufficient number of patients
with rearranged ALK (n = 2) to assess efficacy in this subgroup.
On the basis of a subgroup analysis (data cutoff, December 1,
2015), mOS for EGFR-mutant/ wild-type tumors in cohorts 1, 2,
and 3 was 20.1 months/NE, 9.8/16.3 months, and 7.4/14.7 months,
respectively; mOS for KRAS-mutant/wild-type tumors in cohorts
1, 2, and 3 was NE/20.1 months, 17.7/15.1 months, and 12.1/13.8
months, respectively (Table 2).
DISCUSSION
On the basis of preliminary atezolizumab data suggesting that ORR
may correlate with PD-L1 expression levels, BIRCH was designed
to evaluate ORR in patients with tumors that expressed PD-L1
on $ 5% of TC or IC (TC2/3 or IC2/3). BIRCH met its primary
objective of demonstrating efficacy with atezolizumab mono-
therapy in PD-L1–selected patients with advanced NSCLC. Results
from BIRCH demonstrated clinically meaningful efficacy and
safety of atezolizumab in all lines of therapy. With a minimum
follow-up of 12 months, the ORR in $ 2L patients (cohorts 2 and
3) was 18% to 19% and in 1L (cohort 1) was 22%. The mOS in
$ 2L patients, at 14.6 months, was consistent with prior atezo-
lizumab $ 2L survival results.21,28 An updated survival analysis
Table 1. Patient Demographic Data and Baseline Characteristics (all treated patients [TC2/3 or IC2/3])
Variable Cohort 1: 1L Cohort 2: 2L Cohort 3: $ 3L All Patients
No. of patients 139 268 252 659
Median age, years (range) 67 (35-88) 63 (28-83) 64 (38-84) 64 (28-88)
Male, % 51 61 61 59
Race, %
Asian 9 10 16 12
Black 1 1 2 2
White 88 85 79 84
Other/unknown 2 4 3 3
Ethnicity, %
Hispanic/Latino 1 2 2 2
Not Hispanic/Latino 91 95 94 94
Not reported/unknown 8 3 4 5
ECOG PS 1, % 57 63 68 64
Current/previous tobacco use, % 84 82 83 83
Nonsquamous histology, % 77 69 72 72
Mutation/tested, No. (%)
EGFR*† 13/117 (11) 18/219 (8) 14/207 (7) 45/543 (8)
KRAS* 33/100 (33) 50/200 (25) 54/188 (29) 137/488 (28)
ALK* 3/79 (4) 2/151 (1) 4/146 (3) 9/376 (2)
TC3 or IC3 status, % 47 46 46 46
NOTE. TC3 or IC3 = TC $ 50% or IC $ 10% PD-L1–expressing cells, respectively; TC2/3 or IC2/3 = TC or IC $ 5% PD-L1–expressing cells, respectively.
Abbreviations: 1L, first line; 2L, second line; 3L, third line; ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth
factor receptor; IC, tumor-infiltrating immune cells; PS, performance status; TC, tumor cells.
*Mutational status was not required at enrollment; limited data available.
†Patients were considered EGFRmutant for the analysis if their tumor tested positive for at least one of the following mutations: exon 19 deletions or insertions, L858R,
exon 20 insertion, G719X, L861Q, or S768I. Three patients with a T790Mmutation were not included in this analysis; two of these patients also had an exon 19 deletion.
On the basis of a data cutoff of December 1, 2015.
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(minimum 20-month follow-up) showed that OS data continue to
mature, with an mOS of 23.5 months for 1L patients (26.9 months
for the TC3 or IC3 subgroup), which compares favorably to historical
data with combination chemotherapy. A minority of patients (1.1%)
received immunotherapy after atezolizumab, making subsequent
immunotherapy an unlikely factor for influencing OS results.
Subgroup analyses conducted by varying PD-L1 levels support
the hypothesis that atezolizumab treatment results in improvement
in radiographic end points (eg, ORR) in patients with tumors that
have the highest levels of PD-L1 expression (TC3 or IC3).21,23,24
ORR was higher in the TC3 or IC3 subgroup for both 1L and
$ 2L (Table 2), although in 1L patients it was comparable to
chemotherapy.1,2 PFS was greatest in 1L patients (cohort 1) but
similar between TC3 or IC3 and TC2/3 or IC2/3 patients (5.6 and
5.4 months, respectively). In previously treated patients (cohorts 2
and 3), PFS was modestly higher in TC3 or IC3 patients versus
TC2/3 or IC2/3 patients.
Unlike ORR and PFS, the OS benefit seemed to be independent
of PD-L1 status. For both the TC2/3 or IC2/3 patients and TC3 or IC3
subgroup, atezolizumab treatment seemed to result in a clinically
meaningful OS improvement relative to chemotherapy historical
controls (23.5 months v 10 to 12 months with platinum-based
chemotherapy for patients who received 1L treatment).2,26,27 Simi-
lar results were seen in the POPLAR (ClinicalTrials.gov iden-
tifier: NCT01903993) and OAK (ClinicalTrials.gov identifier:
NCT02008227) trials, in which investigator-assessed ORR and me-
dian PFS results underestimated the broad OS benefit seen with
atezolizumab versus docetaxel.21,28 In these studies, PD-L1 status can
enrich for clinical efficacy with radiographic end points such as ORR,
but may play less of a role with OS. Efforts are underway to compare
different PD-L1 immunohistochemistry assays and to identify ad-
ditional predictive biomarkers across various efficacy end points.
To our knowledge, BIRCH was among the first trials to show,
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Fig 2. Estimated Kaplan-Meier overall
survival for patients with advanced non–
small-cell lung cancer treated with atezoli-
zumab in the BIRCH trial, by cohort. (A)
TC2/3 or IC2/3 group (intent-to-treat pop-
ulation), and (B) TC3 or IC3 subgroup. TC3
or IC3 = TC $ 50% or IC $ 10% PD-L1–
expressing cells, respectively; TC2/3 or
IC2/3 = TC or IC $ 5% PD-L1–expressing
cells, respectively. Cohort 1 = 1L; cohort 2
= 2L; cohort 3 = $ 3L. On the basis of an
updated data cutoff of August 1, 2016. IC,
tumor-infiltrating immune cells; NE, not
estimable; TC, tumor cells.
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patients with NSCLC. These results seem to confirm the pre-
liminary 1L activity seen in the FIR trial (ClinicalTrials.gov
identifier: NCT01846416), which reported a similar ORR (26%)
and 1-year OS rate of 73% in a small 1L cohort.22
Study limitations are similar to those of other single-
arm phase II trials. Although BIRCH was an open-label trial,
the primary efficacy end point was assessed by an IRF that was
blinded to all clinical data except prior cancer treatment/surgery
information, which minimized potential bias. Historical ORRs
with chemotherapy were used for comparison with atezolizumab
because chemotherapy was the standard of care for advanced
NSCLC when BIRCH was initiated.
Subgroup analyses found no clear association between
response to atezolizumab and tumor histology. Efficacy was
seen with both squamous and nonsquamous tumors, similar to
POPLAR results.21 Although mutational data were limited (par-
ticularly for ALK), results presented herein indicate that atezoli-
zumab had activity in both wild-type and mutated tumors;
however, atezolizumab seems less active in EGFR-mutated tumors.
This is consistent with other data suggesting that EGFR-mutated
NSCLC may have lower response to PD-L1/PD-1 inhibitors.29
Atezolizumab was well tolerated in all patients in BIRCH. The
safety profile was consistent with previous atezolizumab mono-
therapy trials.21-23 Treatment-related toxicities were generally
manageable and consistent across multiple lines of therapy, with
grade 3 to 4 TRAEs in 9% of patients in cohort 1 and in 13% of
patients in both cohorts 2 and 3. No unexpected safety signals or
significant differences in AEs or SAEs were seen across cohorts. The
incidence of AEs resulting in atezolizumab withdrawal (# 8% across
all cohorts) was similar to that in POPLAR (8%).20 The TRAE
profile noted in this and in other single-agent atezolizumab tri-
als21-23 is distinct from that seen with chemotherapy. The incidence
of atezolizumab-related pneumonitis (3.3%) was consistent with
prior studies.21,22 In NSCLC trials of other PD-L1/PD-1 inhibitors,
pneumonitis (all grades) occurred at an incidence of 1% to 6%.6-8,11
Results of 1L phase III trials were recently reported for PD-1
inhibitors. A significant benefit in ORR (45% v 28%), PFS (me-
dian, 10.3 v 6.0 months; hazard ratio, 0.50), and OS (median
not reached; hazard ratio, 0.60) was demonstrated with pem-
brolizumab versus chemotherapy in PD-L1–selected patients
($ 50% TC staining for PD-L1).11 In contrast, a randomized phase
III trial of single-agent nivolumab versus investigator’s-choice
chemotherapy in PD-L1–selected patients ($ 1% PD-L1 tumor
staining) did not meet its primary end point of improved PFS or
OS, even in patients with higher PD-L1 staining ($ 50% TC
Table 3. Safety Summary (all treated patients)
Variable
No. of Patients (%)
Cohort 1 Cohort 2 Cohort 3 All Patients
No. of patients 139 268 252 659
Total No. of patients with at least one AE 127 (91) 247 (92) 244 (97) 618 (94)
Adverse events
Total No. of AEs 1,291 2,512 2,575 6,378
Grade 3 or 4 56 (40) 108 (40) 111 (44) 275 (42)
Grade 5 2 (1) 10 (4) 9 (4) 21 (3)
TRAEs
All grades 81 (58) 173 (65) 175 (69) 429 (65)
Grade 3 or 4 13 (9) 35 (13) 33 (13) 81 (12)
Grade 5 0 0 1 (0.4) 1 (0.2)
SAEs 46 (33) 101 (38) 105 (42) 252 (38)
AEs leading to withdrawal from atezolizumab* 8 (6) 20 (8) 15 (6) 43 (7)
AEs leading to dose interruption 36 (26) 68 (25) 83 (33) 187 (28)
TRAEs leading to withdrawal from atezolizumab 5 (4) 4 (2) 6 (2) 15 (2)
NOTE. On the basis of a data cutoff of December 1, 2015.
Abbreviations: AE, adverse event; SAE, serious adverse event; TRAE, treatment-related adverse event.
*Causes of atezolizumab withdrawal (any grade; grade 3 to 4) occurring at an incidence $ 0.5% were pneumonitis (1%; 1%) and pneumonia (1%; 0%).
Table 4. Adverse Events
Type of Adverse Event
Any Grade,
No. (%)
Grade 3 to 4,
No. (%)
TRAE ($ 5% of treated patients)*,†
Fatigue 122 (19) 7 (1)
Diarrhea 71 (11) 2 (0)
Nausea 73 (11) 4 (1)
Pruritus 65 (10) 0
Pyrexia 54 (8) 1 (0)
Decreased appetite 53 (8) 1 (0)
Asthenia 50 (8) 3 (1)
Rash 50 (8) 9 (1)
Arthralgia 39 (6) 2 (0)
AE of special interest (. 1% of treated
patients)
Rash 70 (11) 3 (1)
Hypothyroidism 30 (5) 2 (0)
AST increased 26 (4) 5 (1)
ALT increased 23 (4) 2 (0)
Pneumonitis 26 (4) 11 (2)
Rash maculopapular 13 (2) 2 (0)
Colitis 10 (2) 3 (1)
Peripheral neuropathy 15 (2) 0
NOTE. On the basis of a data cutoff of December 1, 2015.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, as-
partate aminotransferase; TRAE, treatment-related adverse event.
*TRAEs that occurred within 30 days from last day of atezolizumab
administration.
†Grade 5 all-cause AEs: pneumonia (0.5%), lung infection, acute coronary
syndrome, cardiac arrest, cardiac failure, cerebrovascular accident, hepatic
failure, internal hemorrhage, pneumonia aspiration, pneumonitis, respiratory
distress, septic shock, cerebral infarction, and respiratory failure (all , 0.3%).
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staining).30 Ongoing phase III trials are evaluating 1L atezolizumab
versus chemotherapy in PD-L1–selected patients or atezolizumab
with chemotherapy in PD-L1–unselected patients.
In conclusion, data from BIRCH confirmed that single-agent
atezolizumab provided clinical benefit in patients with advanced
NSCLC, with an mOS of approximately 2 years in 1L patients. Efficacy
was also observed in $ 2L patients and in patients with or without
drivermutations. For patientswith PD-L1–expressing tumors, response
rates were higher with atezolizumab versus historical chemotherapy,
and patients with TC3 or IC3 tumors had numerically higher ORRs
versus those with TC2/3 or IC2/3 tumors. Ongoing randomized phase
III trials are comparing atezolizumab monotherapy with combination
chemotherapy or comparing chemotherapy with and without atezo-
lizumab in patients with chemotherapy-näıve advanced NSCLC.
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Fig A1. Best change in sum of the longest diameters (SLD) from baseline by cohort, on the basis of an independent review facility assessment. (A) Cohort 1 (1L), (B)
cohort 2 (2L), and (C) cohort 3 ($ 3L). Complete responders are indicated in blue, partial responders in gold, patients with stable disease in red, and patients experiencing
disease progression in gray. aPatientswith TC3 or IC3 PD-L1 immunohistochemistry status. On the basis of a data cutoff of December 1, 2015. 1L, first line; 2L, second line;
3L, third line; IC, tumor-infiltrating immune cells; PD-L1, programmed death-ligand 1; TC, tumor cells; TC3 or IC3 = TC $ 50% or IC $ 10% PD-L1–expressing cells,
respectively.
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Fig A2. Objective response rates (ORR) for tobacco use and histology patient subgroups shown by cohort as determined by an independent review facility (Response
Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Error bars represent 95% CIs. On the basis of a data cutoff of December 1, 2015.
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Fig A3. Estimated Kaplan-Meier progression-free survival (by independent review facility) curves by PD-L1 status for patients with advanced non–small-cell lung cancer
treatedwith atezolizumab in the BIRCH trial. TC2 or IC2 patients were determined by excluding TC3 or IC3 patients from TC2/3 or IC2/3 patients. (A) Cohort 1 (1L), (B) cohort
2 (2L), and (C) cohort 3 ($ 3L). On the basis of a data cutoff of December 1, 2015. 1L, first line; 2L, second line, 3L, third line; IC, tumor-infiltrating immune cells; PD-L1,
programmed death-ligand 1; TC, tumor cells; TC2/3 or IC2/3 = TC or IC$ 5%PD-L1–expressing cells, respectively; TC3 or IC3 = TC$ 50% or IC$ 10% PD-L1–expressing
cells, respectively.
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Table A2. Independent Review Facility–Assessed Objective Response Rates (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) Versus Historical
Data for All Subgroups
Line of Therapy (ordered




Response Rate (%)† ORR, % (95% CI)‡
$ 3L TC2/3 or IC2/3 253 5 17 (13 to 23)
$ 3L TC3 or IC2/3 236 5 18 (14 to 24)
$ 3L (cohort 3) TC3 or IC3 115 5 27 (19 to 36)
$ 2L TC2/3 or IC2/3 520 7 17 (14 to 21)
$ 2L TC3 or IC2/3 483 7 18 (15 to 22)
$ 2L (cohorts 2/3) TC3 or IC3 237 7 25 (20 to 31)
All lines (all three cohorts) TC3 or IC3 302 15 26 (21 to 31)
NOTE. On the basis of a data cutoff of May 28, 2015. Data analysis was performed approximately 6months after the last patient was enrolled. Objective response rates
(ORRs) were 17% to 19% for patients with TC2/3 or IC2/3 tumors and 26% to 27% for the TC3 or IC3 subgroup. The median overall survival (95% CI) for patients with
TC2/3 or IC2/3 tumors was 14.0 months (14.0 months to NE), NE (11.2 months to NE), and NE (8.4 months to NE) for cohorts 1, 2, and 3, respectively, with 6-month
cumulative survival rates of 82%, 76%, and 71%, respectively. (The median survival was immature for the TC3 or IC3 subgroup.)
Abbreviations: 2L, second line; 3L, third line; IC, tumor-infiltrating immune cells; NE, not estimable; PD-L1, programmed death-ligand 1; TC, tumor cells; TC2/3 or IC2/3 =
TC or IC $ 5% PD-L1–expressing cells, respectively; TC3 or IC3 = TC $ 50% or IC $ 10% PD-L1–expressing cells, respectively.
*PD-L1–expressing TC: TC3 =$ 50%; TC2 =$ 5% and, 50%. Percentage of PD-L1–expressing IC in tumormicroenvironment: IC3 =$ 10%; IC2 =$ 5% and, 10%.
†Prespecified historical control response rates shown were solely on the basis of prior lines of chemotherapy received.
‡P , .001 for each ORR value compared with respective historical chemotherapy control rates.
Table A1. Programmed Death-Ligand 1 Tumor Cells and Tumor-Infiltrating
Immune Cells Scoring Criteria
TC Score
PD-L1 TC Scoring Criteria PD-L1 IC Scoring Criteria
% of PD-L1–Expressing TC IC Score % of Tumor Area
TC3 $ 50% IC3 $ 10%
TC2 $ 5% and , 50% IC2 $ 5% and , 10%
TC1 $ 1% and , 5% IC1 $ 1% and , 5%
TC0 , 1% IC0 , 1%
Abbreviations: IC, tumor-infiltrating immune cells; PD-L1, programmed death-
ligand 1; TC, tumor cells.
Table A3. Atezolizumab Efficacy by TC2 or IC2 Programmed Death-Ligand 1 Status
Cohort No. of Patients ORR, No. (%; 95% CI)* Median DOR, Months (95% CI) Median PFS, Months (95% CI)* Median OS, Months (95% CI)
1 74 10 (14; 6 to 23) 5.6 (4.6 to NE) 5.3 (2.8 to 6.9) 20.1 (NE to NE)
2 146 20 (14; 9 to 20) 11.3 (6.9 to NE) 2.6 (1.4 to 2.8) 15.5 (11.9 to NE)
3 136 14 (10; 6 to 17) 11.8 (8.4 to NE) 2.7 (1.5 to 2.8) 11.0 (7.5 to 14.9)
NOTE. On the basis of a data cutoff of December 1, 2015. TC2/3 or IC2/3 excluding TC3 or IC3.
Abbreviations: DOR, duration of response; IC, tumor-infiltrating immune cells; IC2 =$ 5%and, 10%; PFS, progression-free survival; NE, not estimable; ORR, objective
response rate; OS, overall survival; TC, tumor cells; TC2 = $ 5% and , 50%; TC2/3 or IC2/3 = TC or IC $ 5% PD-L1–expressing cells, respectively; TC3 or
IC3 = TC $ 50% or IC $ 10% PD-L1–expressing cells, respectively.
*Assessed by an independent review facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
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